The FDA expands approval of Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis.

Serena Williams’ Wimbledon comeback is over after she withdrew from her doubles match. Williams and sister Venus, given a ...

Week-16 results showed that 69% of risankizumab-treated patients achieved a static Physician Global Assessment of Psoriasis ...

FDA cleared a Besremi prefilled pen as a second delivery option to the prefilled syringe, with no changes to indication, dose schedule, or established safety profile. Ropeginterferon alfa-2b is ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

New flexible, low-carbon NFC chip delivers instant tamper detection, product authentication and deeper brand engagement to protect consumers, ...

A 60-year-old Newberg man has been identified as the motorcyclist who died in a single-vehicle crash on southbound I-5 near the Marquam Bridge ...

FIR filed against two AIIMS Bhopal nurses after a three-year-old cancer patient died from a formalin injection. Inquiry found gross negligence.

Please Don't Scroll Past This Can you chip in? The Internet Archive partners with libraries, archives, and institutions across the globe to preserve cultural heritage that would otherwise be lost ...

ST. CHARLES, Ill., April 8, 2026 /PRNewswire/ -- Chicago Coding Systems (CCS), a leader in comprehensive marking and traceability solutions, today announced the rollout of the LM3612 Custom Syringe ...

SKYRIZI (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1Approval was based on the pivotal Phase 3 OptIMMize-1 ...

President Donald Trump labels Minnesota Congresswoman Ilhan Omar a “fraud” and suggests she may have staged a recent syringe spray incident at her Minneapolis town hall, comments that come as the ...